GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (STU:1A80) » Definitions » Quality Rank

Accelerate Diagnostics (STU:1A80) Quality Rank


View and export this data going back to 2014. Start your Free Trial

What is Accelerate Diagnostics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Accelerate Diagnostics Quality Rank Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerate Diagnostics (STU:1A80) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (STU:1A80) » Definitions » Quality Rank
Comparable Companies
NMTC LUDG MDAI CODX NSYS RPID RMSL IINN BSGM SNWV ABT SYK BSX MDT XTER:SHL EW DXCM SZSE:300760 XAMS:PHIA ZBH
Traded in Other Exchanges
AXDX:USA AXDX:Mexico 1A80:Germany
Address
3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Website
https://www.acceleratediagnostics.com
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.